Forum Uniquely Brings Together Leading Family Offices and Their Foundations Seeking Impact Investment, Grant-Giving, and Philanthropy Opportunities within Health and Life Sciences
BETHLEHEM, PA / ACCESSWIRE / May 7, 2015 / Cerora, Inc., a GE (NYSE) StartUp Health Academy Entrepreneurship Program and Ben Franklin Technology Partners of Northeastern Pennsylvania neurotechnology company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 10 to May 14 in La Jolla, California. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading research institutions, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of leading family offices, Cavendish Impact Forums are hosted by leading institutions around the world and take place three times each year. The next Forum is being co-hosted by the community of La Jolla, California including The University of California San Diego, The J. Craig Venter Institute, The Scripps Research Institute, The Sanford-Burnham Medical Research Institute, The Sanford Consortium for Regenerative Medicine, and The Institute of the Americas.
Michael Moffat, Cavendish co-founder and Chief Executive Officer explains, "The theme of our La Jolla, California Forum is a 'Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World.' With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Cerora's research and scientific insights in developing and commercializing a portable, accurate, and easy-to-use brain health assessment tool positions them to make a major contribution to the paradigm shift from a subjective opinion to an objective biosensor-based assessment in neurodiagnostic information with an initial focus on concussion and mild traumatic brain injury."
"We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach for mobile patient monitoring, which enables remote diagnosis and management of a variety of brain health issues people face globally. We are excited at the prospects of our platform helping patients with concussion (mild traumatic brain injury) as well as many other types of brain related issues, including injury, neurological, psychiatric, and tumor," said Adam J. Simon, Cerora's CEO. "We welcome the chance to interact with many of world's most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world."